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Abstract: The role of drugs in new cancer occurrence and cancer-related death is a major 
concern. Recently, a meta-analysis raised the possibility that angiotensin receptor blockers 
(ARBs) might have an adverse effect on patients. This generated a significant debate until the 
publication of two further meta-analyses, neither of which demonstrated an increased risk of 
new cancer occurrence or cancer-related death with the use of ARBs in patients with hyperten-
sion, heart failure, and/or nephropathy. This illustrates that the results of meta-analyses should 
be interpreted cautiously and critically as bias, such as selection bias, might lead to erroneous 
conclusions. Overall, the bulk of evidence today indicates that ARBs are not associated with 
increased cancer risk.
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Introduction
Hypertension and cancer are both major health issues worldwide. They have stimulated 
research into pharmacological products to decrease the burden associated with the 
diseases. However, hypertension and cancer are not perceived the same way, as the 
negative image of cancer far outweighs that of hypertension.
Whenever approval is sought for a new drug, regulators from medical agencies 
such as the US Food and Drug Administration and the European Medicines Agency 
are faced with the difficult task of evaluating the risk–benefit ratio. This involves, on 
one hand, quantifying efficacy endpoints from controlled clinical trials and, on the 
other hand, quantifying harms reported from clinical trials and other sources such 
as spontaneous adverse event reports. However, the principles and methodology for 
risk–benefit assessment are currently lacking and quantitative risk–benefit assessment 
is not expected to replace qualitative evaluation according to the European Medicines 
Agency,1 even if decision analysis is introduced.2 Importantly, drugs are assessed at the 
population level, but patients and health professionals often focus their consideration 
on the risks and benefits for individuals.
In the case of hypertension, the availability of oral antihypertensive drugs has, 
according to findings from large controlled trials, decreased cardiovascular mortality 
and morbidity compared with placebo. These findings have been confirmed in sev-
eral meta-analyses.3–5 However, the safety of these drugs, with regard to cancer risk, 
has been questioned from the time they were first marketed. This has been the case 
for reserpine,6 diuretics,7,8 calcium channel blockers,9 and angiotensin-converting 
enzyme inhibitors.10 On each occasion, a debate, secondary to conflicting results, has 
followed the release of these publications, resulting in the generation of new reviews 
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and meta-analyses.11–13 More recently, the question of cancer 
occurrence in conjunction with the use of angiotensin II 
receptor blockers (ARBs) has also been addressed.
Meta-analyses of ARBs and cancer
The first meta-analysis of the relationship between ARBs and 
cancer was released on June 14, 2010.14 It included nine con-
trolled randomized trials: five trials, with data from 61,590 
patients, assessing new cancer risk as a primary objective,15–19 
and eight trials, with data from 93,515 patients, assessing the 
risk of cancer-related death15,17–23 as a secondary objective.
Follow-up was at least 1 year and the number of patients 
included had to be at least 100. Of the patients included in the 
primary analysis, 85.7% were taking telmisartan. The analy-
sis showed that the risk ratio (RR) of new cancer in patients 
randomized to ARBs compared with patients randomized to 
placebo was 1.08 (95% confidence interval [CI] 1.01–1.15). 
There was no significant difference in the risk of cancer death 
(RR 1.07, 95% CI 0.97–1.18) between patients randomized 
to ARBs and those randomized to placebo. The authors con-
cluded that ARBs were associated with a modestly increased 
risk of new cancer occurrence. The absolute increase risk of 
cancer over a 4-year period was 1.2%, which had to be inter-
preted, according to authors, in the view of the estimated 41% 
lifetime cancer risk. Some limitations acknowledged were: 
the pooled results were taken from trials not designated to 
explore cancer outcomes as primary outcome measures, the 
adjudication of cancer diagnoses was not uniform among the 
included studies, the possibility of publication bias, and the 
absence of access to individual data. The authors encouraged 
further investigations of ARBs and cancer risk.
The second meta-analysis was released online in the same 
journal on November 30, 2010.24 The authors undertook a 
traditional direct-comparison meta-analysis, a multiple-
comparison or network analysis, and trial sequential analyses. 
The primary objectives were cancer risk and cancer-related 
deaths with antihypertensive drugs. Follow-up had to be at 
least 1 year and at least 100 patients had to be included in the 
trials. Of the 70 randomized control trials (324,168 partici-
pants), 23 included ARBs.15–22,25–39 Of note, two of the trials 
(Valsartan Heart failure trial [Val-Heft] and Candesartan in 
Heart Failure Assessment of reduction in Mortality and Mor-
bidity [CHARM]-added)20,33 were considered as angiotensin-
converting enzyme inhibitors (ACE-Is) plus ARB trials, 
because ARBs were given on top of ACE-Is. Therefore, 21 
trials, enrolling more than 120,000 patients, were included 
in the meta-analyses on ARBs. The mean follow-up was 3.5 
years and heterogeneity was low.
The results from the multiple-comparison meta-analyses 
showed that the risk of cancer for each individual antihyper-
tensive agent did not differ significantly from placebo. In 
particular, there was no excessive risk of cancer with ARBs 
(odds ratio 1.01, 95% CI 0.93–1.09). However, the combina-
tion of ACE-Is and ARBs was associated with increased can-
cer risk when compared with placebo (odds ratio 1.14, 95% 
CI 1.02–1.28) in one model but not in other models (random 
effect models). No difference in risk of cancer-related death 
was observed between placebo and antihypertensive drugs. 
For ARBs, the death rate was 1.33% with no increased risk 
(odds ratio 1.00, 95% CI 0.87–1.15). Based on trial sequen-
tial analysis, results suggested that there was no evidence of 
a 5%–10% relative-risk increase of cancer and cancer-related 
death with any individual class of antihypertensive drugs 
studies. Limitations acknowledged by authors included: 
lack of adjustment for drug dosage or compliance to the 
assigned treatment, possible outcome measure reporting 
bias, and multiple testing. Since medications were grouped 
in classes, increase in cancer risk with an individual drug 
could not be excluded. The authors also pointed out that 
antihypertensive drugs are usually prescribed for decades 
and that the mean follow-up was only 3.5 years. They 
concluded that a clinically significant increase in cancer 
risk or cancer-related death was not observed in their large 
comprehensive analysis.
Finally, a third meta-analysis from the ARB Trialists 
Collaboration was published in April 2011 in the Journal 
of Hypertension.40 It included 15 large parallel long-term 
 double-blind clinical trials15–20,22,23,25,30,39,41–45 involving 
138,769 participants. More than 500 participants had to be 
included and the mean follow-up had to be at least 12 months. 
The primary objective of the study was cancer incidence 
in ARB versus non-ARB control treatment. The average 
follow-up ranged from 23 to 60 months.
Overall cancer incidence was 6.16% in participants 
allocated ARBs versus 6.31% in those assigned non-ARB 
treatment (odds ratio 1.00 with 95% CI 0.95–1.04). However, 
the test for heterogeneity was significant. In the secondary 
analysis, no excess of cancer was observed for each indi-
vidual ARB (candesartan, irbesartan, losartan, valsartan, 
telmisartan). Data on cancer death were available in 13 trials. 
Death from cancer occurred in 1.85% of the patients ran-
domized to ARBs and in 1.77% of the patients randomized 
to non-ARBs (odds ratio 1.03, 95% CI 0.95–1.12). The 
test for heterogeneity was not significant. No excess risk of 
cancer was observed with the combination of ACE-Is and 
ARBs. The main limitation acknowledged by authors was 
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the  relatively short duration of exposure to antihypertensive 
drugs. The authors concluded that, in patients with cardio-
vascular disease, heart failure, hypertension, and diabetes, 
there is no significant excess in cancer with the long-term 
use of the ARBs included in their analysis.
Can some meta-analyses be misleading?
Meta-analyses are often seen as the holy grail of evidence 
medicine, having the “strongest” level of evidence that can 
be obtained. However, they are and have been subject to 
criticism.46 Meta-analyses have been developed in an attempt 
to resolve conflicting results from trials addressing similar 
issues. Those who believe in the efficacy of a given interven-
tion tend to use positive (significant) trials to defend a point of 
view, and explain negative trials by a lack of statistical power. 
Conversely, those who do not believe that a given intervention 
has any efficacy will use negative trials as proof of inefficacy 
and will argue that positive (significant) trials are the result of 
chance. To draw conclusion from conflicting results, data have 
to be synthesized and must take into account the possibility 
of underpowered negative trials and the possibility of a type 
I error (false positive) in positive trials.
The main advantages of a meta-analysis over a single trial 
or several trials taken individually are: to increase power, to 
reconcile apparently discordant results, to increase the accu-
racy of the size of the effect of treatment, to test and increase 
the extent of the result to a large number of patients, to 
explain the variability of the results, and, in some cases, to 
notice the lack of reliable data. Key elements of meta-analyses 
are that the synthesis is exhaustive, rigorous, reproducible, 
and quantifiable. Table 1 summarizes some questions to be 
asked when reading a meta-analysis.
In the case of ARBs, critical reading of the meta-analyses 
available is essential, particularly when different meta-
analyses provide divergent results. The conflicting results 
obtained by the three meta-analyses discussed are probably 
best explained by the clinical trials selected for the analyses 
(Table 2), one of the most frequent reasons of discordance. 
Selection criteria and a time effect (new trials available) 
explain the different studies included in the meta-analyses.
Finally, the lack of evidence of a significant effect 
of ARBs on cancer incidence does not necessarily mean 
that there is no effect. This point is often raised in the 
concluding remarks of negative meta-analyses and was 
evident in the meta-analysis of Bangalore et al,24 in which 
the authors refuted a 5.0%–10.0% relative increase in 
the risk of cancer or cancer-related death with the use 
of ARBs.
is there a plausible pathophysiological 
mechanism explaining a causal 
relationship between ARBs and cancer?
From a pathophysiological point of view, most of the evidence 
indicates that the inhibition of the renin angiotensin system 
is protective rather than deleterious with regard to the devel-
opment of cancer. After the publication of a retrospective 
study suggesting lower than expected incidence of lung 
and breast cancer in hypertensive patients taking ACE-Is,47 
possible pathophysiological mechanisms for such a finding 
were explored.48 So far, it has been shown that components 
of the renin angiotensin system are expressed in cancer cells 
from various tissues including the lungs, kidneys, breast, 
and prostate.49 Further, angiotensin II has been shown to 
have a local effect on cell proliferation, angiogenesis, and 
inflammation, in addition to its well-known systemic effects 
on the cardiovascular system. These local effects are mediated 
by the angiotensin II type 1 receptor or the angiotensin II 
type 2 receptor, which have different tissue distribution. 
They can, respectively, activate or inhibit various cascades of 
intracellular protein kinases usually associated with growth 
factors.
The main effect of ARBs on cancer appears to be 
through inhibition of the release of pro-angiogenic factors 
from tumor cells in vitro.50 This has been observed with 
candesartan in various cancer cell lines.51–53 Decrease in the 
expression of the vascular endothelial growth factor receptor 1 
has also been observed.51,53,54 This effect could be mediated 
by an inhibitory effect of ARB on hypoxia-inducible-factor 
and ETS-1 induction, which has been reported in hormone 
refractory prostate cancer cell lines.55 Hence, these studies 
provide a molecular basis suggesting that ARB has a protec-
tive effect against some cancers. However, a few studies have 
shown that ARBs may increase vascular density in cancer 
models, an effect possibly mediated by the angiotensin 
type 2 receptor stimulation.56,57 In stroke models, ARBs 
Table 1 Some questions to be asked when reading a meta-
analysis
Has the research of published trials been extensive?
Have unpublished trials been searched?
Have the trials been included independently of their results?
Have the reasons for exclusion of trials been specified?
Are the trials included in the analysis devoid of methodological flaws?
if heterogeneity was detected, has an explanation been sought?
Are the results of the analysis clinically relevant?
Can the analysis assess the benefit–risk balance?
Does the conclusion reflect the results of the analysis?
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may play an angiogenic role.58,59 Therefore, the angiogenic 
effect of angiotensin II receptor blockade may conceivably 
be organ specific. More basic studies are needed to explain 
the potential role of ARBs in local cell proliferation and 
angiogenesis in more detail.
Risk of cancer in hypertensive patients
As previously mentioned, the potential cancer risk associ-
ated with antihypertensive drugs has been in question since 
these drugs first became available. One of the difficulties 
has been in the determination of the cancer risk associ-
ated with hypertension itself or to factors associated with 
hypertension, such as age, obesity, and blood pressure–
lowering drugs.
Several epidemiological prospective studies have shown 
that high blood pressure is associated with increased cancer 
risk60 and cancer mortality.61–63 In the first of these prospec-
tive studies, which describes the association between blood 
pressure and cancer, Dyer et al observe that the increased risk 
of death from cancer was seen in both treated and untreated 
patients.62 Some have suggested that the causal direction is 
from cancer to hypertension, because the increased risk of 
malignancy is most pronounced among newly diagnosed 
hypertensive patients.60 However, uncertainties persist, 
mainly concerning the effect of the duration of the disease, 
age and sex of patients, and cancer-site specificity.64 For 
example, the effect of time is illustrated in a prospective 
study where a negative association between blood pressure 
and cancer during the first 5 years of follow-up changed 
into a positive association after 13 years of follow-up.65 Of 
note, the mean follow-up of the these prospective epidemio-
logical trials studying the association between hypertension 
and cancer ranged from 9 to 20 years, in comparison with 
a shorter follow-up, usually of less than 5 years, in the 
controlled studies included in the meta-analyses previously 
discussed.14,24,40
Obesity is another example of a risk factor associated with 
both cancer66 and hypertension.67 When the risk of renal cell 
carcinoma was studied in a Swedish cancer registry, both 
higher body mass index and elevated blood pressure were 
independently associated with long-term risk of renal cell 
cancer in men.68 This indicates that although obesity and 
hypertension are associated, they might influence renal cell 
cancer through different mechanisms.
Table 2 Trials included in the three meta-analyses
Trial ARB N Sipahia,14 Sipahib,14 Bangalore24 ARB trialist40
LiFe15 Losartan 9193 x x x x
TROPHY16 Candesartan 772 x x x
TRANSCeND18 Telmisartan 5926 x x x x
ONTARGeT19 Telmisartan 25,620 x x x x
PROFeSS17 Telmisartan 20,332 x x x x
CHARM overall23 Candesartan 7599 x x* x
OPTiMAAL21 Losartan 5477 x x
VALiANT22 Valsartan 14,703 x x x
VAL-HeFT20 Valsartan 5010 x x x
i-PReSeRVe39 irbesartan 4128 x x
ACTiVe-i42 irbesartan 9016 x
iDNT25 irbesartan 1715 x x
VALUe30 Valsartan 15,245 x x
NAViGATOR41 Valsartan 9306 x
SCOPe16 Candesartan 4964 x
DiReCT43, 45 Candesartan 5231 x
ALPiNe32 Candesartan 393 x
e-COST37 Candesartan 2048 x
GiSSi-AF27 Valsartan 1442 x
HiJ-CReAT31 Candesartan 2049 x
iRMA 235 irbesartan 608 x
JiKei34 Valsartan 3081 x
KYOTO Heart study36 Valsartan 3031 x
ReNAAL26 Losartan 1513 x
ROAD29 Losartan 360 x
Suzuki et al38 Valsartan, candesartan, losartan 366 x
Notes: *Only CHARM added33 and CHARM alternative.28 aAssessment of new cancer risk; bassessment of cancer-related death risk.
Abbreviation: ARB, angiotensin receptor blocker.
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Conclusion
At a time when evidence-based medicine plays an increasing 
role in all fields of health care, meta-analyses have become 
an obligatory step in many areas of medicine. Their strength 
lies in compiling observations made in several trials, which 
provides increased power, secondary to the large number of 
participants included, to detect even small differences in out-
comes. However, the selection or nonselection of trials within 
an analysis can strongly influence the results, as is illustrated 
in this review. For this reason, the search for trials has to be 
exhaustive and the selection criteria have to be well documented 
to avoid unrecognized selection bias.69 Further, it has to be kept 
in mind that a population-level benefit observed in a meta-
analysis does not necessarily apply to the individual patient.
The media buzz generated by the release of the first 
meta-analysis14 that observed an increased cancer risk with 
ARBs, currently some of the most prescribed cardiovascular 
drugs, has, however, prompted the scientific community to 
respond with new meta-analyses24,40 and the US Food and 
Drug Administration to release a statement70 concluding 
that the proven benefits of ARBs continue to outweigh their 
potential risk.
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